We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-6 of 6

More EU monitoring of patent settlements in the pharma sector

  • CMS Cameron McKenna
  • -
  • European Union
  • -
  • January 24 2011

On 17 January 2011, the European Commission announced that it has launched another round of its monitoring of patent settlement agreements between pharmaceutical companies

Pharmaceutical patent settlement agreements - European Commission scrutiny continues

  • CMS Cameron McKenna
  • -
  • European Union
  • -
  • July 14 2011

On 6 July 2011, the European Commission published the results of its second round of monitoring of pharmaceutical patent settlement agreements

Current issues in lifesciences

  • CMS Cameron McKenna
  • -
  • Czech Republic, European Union
  • -
  • January 11 2012

The lifescience sector is driven by development and innovation

Court of Justice clarifies exclusion against patenting of embryonic stem cells

  • CMS Cameron McKenna
  • -
  • European Union, Germany
  • -
  • October 26 2011

Under Article 5 of EU Directive 9844EC the “Biotech Directive”, the human body, at the various stages of its formation and development, and the simple discovery of one of its elements, including the sequence or partial sequence of a gene, cannot constitute patentable inventions

Advocate General would reject AstraZeneca's appeal against abuse of dominance

  • CMS Cameron McKenna
  • -
  • European Union
  • -
  • May 16 2012

On 15 May 2012, Advocate General Mazak of the European Court (ECJ) delivered his opinion on AstraZeneca's practices involving anti-ulcer product Losecomeprazole

AstraZeneca judgment: don’t game the system

  • CMS Cameron McKenna
  • -
  • European Union
  • -
  • December 12 2012

In a long-awaited judgment dated 6 December 2012, the European Court of Justice (ECJ) has confirmed that certain brand protection strategies may infringe the EU competition rules

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy